vs
ICHOR HOLDINGS, LTD.（ICHR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
ICHOR HOLDINGS, LTD.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$223.6M vs $207.3M），ICHOR HOLDINGS, LTD.净利率更高（-7.1% vs -62.0%，领先54.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -4.2%），ICHOR HOLDINGS, LTD.自由现金流更多（$5.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 5.4%）
Ichor Holdings Ltd.是面向全球半导体制造领域的关键流体输送系统、子系统及相关组件的设计、制造供应商，产品集成于晶圆前端加工设备，为北美、东亚、欧洲的领先半导体设备与芯片厂商提供先进逻辑、存储芯片生产配套支持。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ICHR vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $223.6M | $207.3M |
| 净利润 | $-16.0M | $-128.6M |
| 毛利率 | 9.4% | — |
| 营业利润率 | -6.2% | -54.7% |
| 净利率 | -7.1% | -62.0% |
| 营收同比 | -4.2% | 25.9% |
| 净利润同比 | -304.8% | 3.5% |
| 每股收益（稀释后） | $-0.46 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $223.6M | $207.3M | ||
| Q3 25 | $239.3M | $159.9M | ||
| Q2 25 | $240.3M | $166.5M | ||
| Q1 25 | $244.5M | $139.3M | ||
| Q4 24 | $233.3M | $164.6M | ||
| Q3 24 | $211.1M | $139.5M | ||
| Q2 24 | $203.2M | $147.0M | ||
| Q1 24 | $201.4M | $108.8M |
| Q4 25 | $-16.0M | $-128.6M | ||
| Q3 25 | $-22.9M | $-180.4M | ||
| Q2 25 | $-9.4M | $-115.0M | ||
| Q1 25 | $-4.6M | $-151.1M | ||
| Q4 24 | $-3.9M | $-133.2M | ||
| Q3 24 | $-2.8M | $-133.5M | ||
| Q2 24 | $-5.1M | $-131.6M | ||
| Q1 24 | $-9.0M | $-170.7M |
| Q4 25 | 9.4% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 11.3% | — | ||
| Q1 25 | 11.7% | — | ||
| Q4 24 | 11.6% | — | ||
| Q3 24 | 13.2% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 11.4% | — |
| Q4 25 | -6.2% | -54.7% | ||
| Q3 25 | -8.1% | -106.9% | ||
| Q2 25 | -2.0% | -64.8% | ||
| Q1 25 | -0.5% | -102.6% | ||
| Q4 24 | -0.5% | -74.3% | ||
| Q3 24 | -0.2% | -94.6% | ||
| Q2 24 | -1.1% | -79.1% | ||
| Q1 24 | -1.9% | -151.9% |
| Q4 25 | -7.1% | -62.0% | ||
| Q3 25 | -9.6% | -112.8% | ||
| Q2 25 | -3.9% | -69.0% | ||
| Q1 25 | -1.9% | -108.5% | ||
| Q4 24 | -1.7% | -80.9% | ||
| Q3 24 | -1.3% | -95.7% | ||
| Q2 24 | -2.5% | -89.5% | ||
| Q1 24 | -4.5% | -156.8% |
| Q4 25 | $-0.46 | $-1.28 | ||
| Q3 25 | $-0.67 | $-1.81 | ||
| Q2 25 | $-0.28 | $-1.17 | ||
| Q1 25 | $-0.13 | $-1.57 | ||
| Q4 24 | $-0.11 | $-1.34 | ||
| Q3 24 | $-0.08 | $-1.40 | ||
| Q2 24 | $-0.15 | $-1.52 | ||
| Q1 24 | $-0.30 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.3M | $421.0M |
| 总债务越低越好 | $123.5M | — |
| 股东权益账面价值 | $663.9M | $-80.0M |
| 总资产 | $942.9M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
| Q4 25 | $98.3M | $421.0M | ||
| Q3 25 | $92.5M | $202.5M | ||
| Q2 25 | $92.2M | $176.3M | ||
| Q1 25 | $109.3M | $127.1M | ||
| Q4 24 | $108.7M | $174.0M | ||
| Q3 24 | $116.4M | $150.6M | ||
| Q2 24 | $114.3M | $480.7M | ||
| Q1 24 | $102.1M | $112.3M |
| Q4 25 | $123.5M | — | ||
| Q3 25 | $123.5M | — | ||
| Q2 25 | $125.0M | — | ||
| Q1 25 | $126.8M | — | ||
| Q4 24 | $128.5M | — | ||
| Q3 24 | $130.3M | — | ||
| Q2 24 | $130.2M | — | ||
| Q1 24 | $131.9M | — |
| Q4 25 | $663.9M | $-80.0M | ||
| Q3 25 | $676.2M | $9.2M | ||
| Q2 25 | $694.1M | $151.3M | ||
| Q1 25 | $700.4M | $144.2M | ||
| Q4 24 | $698.3M | $255.0M | ||
| Q3 24 | $697.3M | $346.8M | ||
| Q2 24 | $694.9M | $432.4M | ||
| Q1 24 | $697.2M | $140.3M |
| Q4 25 | $942.9M | $1.5B | ||
| Q3 25 | $966.6M | $1.2B | ||
| Q2 25 | $985.1M | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $995.6M | $1.5B | ||
| Q3 24 | $975.9M | $1.5B | ||
| Q2 24 | $947.7M | $1.6B | ||
| Q1 24 | $957.4M | $1.3B |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.18× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.19× | — | ||
| Q1 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $5.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 2.6% | -48.6% |
| 资本支出强度资本支出/营收 | 1.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-6.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $9.2M | $-99.8M | ||
| Q3 25 | $9.2M | $-91.4M | ||
| Q2 25 | $-7.5M | $-108.3M | ||
| Q1 25 | $19.0M | $-166.5M | ||
| Q4 24 | $-2.5M | $-79.3M | ||
| Q3 24 | $8.1M | $-67.0M | ||
| Q2 24 | $17.5M | $-77.0M | ||
| Q1 24 | $4.8M | $-190.7M |
| Q4 25 | $5.9M | $-100.8M | ||
| Q3 25 | $2.1M | $-92.7M | ||
| Q2 25 | $-14.8M | $-110.7M | ||
| Q1 25 | $496.0K | $-167.8M | ||
| Q4 24 | $-6.9M | $-79.5M | ||
| Q3 24 | $2.2M | $-68.6M | ||
| Q2 24 | $14.6M | $-79.0M | ||
| Q1 24 | $314.0K | $-193.9M |
| Q4 25 | 2.6% | -48.6% | ||
| Q3 25 | 0.9% | -58.0% | ||
| Q2 25 | -6.2% | -66.5% | ||
| Q1 25 | 0.2% | -120.5% | ||
| Q4 24 | -3.0% | -48.3% | ||
| Q3 24 | 1.0% | -49.2% | ||
| Q2 24 | 7.2% | -53.7% | ||
| Q1 24 | 0.2% | -178.2% |
| Q4 25 | 1.5% | 0.5% | ||
| Q3 25 | 3.0% | 0.8% | ||
| Q2 25 | 3.0% | 1.5% | ||
| Q1 25 | 7.6% | 1.0% | ||
| Q4 24 | 1.9% | 0.1% | ||
| Q3 24 | 2.8% | 1.2% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 2.2% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICHR
| Other | $101.6M | 45% |
| US | $67.4M | 30% |
| Other Countries | $29.7M | 13% |
| Europe | $24.9M | 11% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
